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Abstract
Aims/Background-All components nec-
essary for the formation of angiotensin II,
the biologically active product of the
renin-angiotensin system (RAS), have
been demonstrated in ocular tissue or
vitreous and subretinal fluid. The tissue
concentrations of renin were too high to
be explained by admixture of blood. This
raises the possibility of an intraocular
RAS, independent of the RAS in the cir-
culation.
Methods-In the present study, gene
expression of RAS components in differ-
ent parts of enucleated human eyes was
investigated as evidence for tissue specific
production.
Results-By using pooled tissue samples
renin mRNA could be detected with the
RNAse protection assay in retinal pigment
epithelium (RPE) choroid, but not in
neural retina or sclera. With reverse
transcription polymerase chain reaction
(RT-PCR), renin mRNA was detected in
individual samples of RPE choroid and
neural retina, and not anterior uveal tract
or sclera. Angiotensinogen and angio-
tensin converting enzyme (ACE) gene
expression could be demonstrated by
RT-PCR in individual RPE choroid and
neural retina samples and marginally in
sclera samples.
Conclusion-These results support the
concept of intraocular synthesis of angio-
tensin II, independent of renin, angio-
tensinogen, and ACE in the circulation.
Since gene expression was highest in
ocular parts, which are highly vascu-
larised, local angiotensin II may be
involved in blood supply and/or patho-
logical vascular processes such as neovas-
cularisation in diabetic retinopathy.
(BrJ Ophthalmol 1996; 80: 159-163)
The renin-angiotensin system (RAS) plays an
important role in the control of blood pressure
and electrolyte homeostasis. The enzyme renin
cleaves its substrate, angiotensinogen, to form
angiotensin I. Angiotensin I is then converted
by angiotensin converting enzyme (ACE) to
angiotensin II, a potent vasoconstrictor and a
stimulant of aldosterone release.
Components of the RAS are present both in
the circulating blood and in tissues, including
the eye. 1-7 Their presence in the eye cannot be
explained by admixture with blood,' 2 7 sug-
gesting that a local, intraocular, RAS may
exist. Expression of RAS component genes in
specific ocular tissues, however, has not been
demonstrated so far. In a variety of other
tissues - for example, adrenal, placenta,
gonads, and brain, such expression has now
been detected,8-'0 thereby raising the pos-
sibility of local production of angiotensin II
independent of the circulating RAS. "1 12
The function of a local RAS in the eye is
unknown. Angiotensin II receptors have been
detected in retinal blood vessels, suggesting
that angiotensin II may be involved in the
regulation of retinal vascular tone.'3 14 Apart
from a role in the control of ocular perfusion,
angiotensin II may also affect the regulation of
aqueous fluid haemodynamics, since local
application of ACE inhibitors lowers intra-
ocular pressure.'5 The RAS has also been
implicated in diseases of the eye. High levels of
prorenin, the inactive precursor of renin, have
been found in plasma of diabetic subjects and
these high levels correlated with the presence
of microvascular complications, proliferative
retinopathy in particular.'6 17 Moreover,
vitreous fluid obtained during eye surgery from
diabetic patients with proliferative retinopathy
contained higher levels of prorenin than
vitreous obtained from non-diabetic subjects
without retinopathy,' suggesting that the
intraocular RAS may be activated in diabetic
subjects with proliferative retinopathy.
In view of its mitogenic and trophic actions,
as well as its influence on angiogenesis,'8 19
angiotensin II produced locally in the eye may
play a role in the development of proliferative
diabetic retinopathy. In order to demonstrate
local generation of RAS components in the
eye, we investigated gene expression of renin,
angiotensinogen, and ACE in neural retina,
retinal pigment epithelium (RPE) choroid,
159
Wagner, Danser, Derkx, de Jong, Paul, Mullins, Schalekamp, Ganten
anterior uveal tract, and sclera obtained from
enucleated human eyes both by RNAse pro-
tection assay and by reverse transcription
polymerase chain reaction (RT-PCR).
Materials and methods
OCULAR TISSUE COLLECTION
Ocular tissues were removed from enucleated
eyes and frozen in liquid nitrogen within 1-2
minutes after enucleation. The eyes were
obtained from 18 subjects (12 men and six
women; mean age 54, range 26-78 years). The
indications for enucleation were: choroidal
melanoma (n= 11), ciliary body melanoma
(n= 1), phthisis bulbi (n=2), neovascular
glaucoma (n=2), bullous keratopathy in a
blind eye (n=l) and an inflamed blind eye
after trauma (n= 1). In the case of ocular
melanoma only tissue remote from the tumour
site was isolated.
Depending on what part of the eye had to be
sent to the pathology department, neural
retina, RPE choroid, anterior uveal tract, or
sclera were isolated as follows. The isolation
was performed at room temperature. Each eye
was cut equatorially at the ora serrata, and the
anterior segment was lifted off. The vitreous
body was isolated by gently shaking it out of
the eye cup. The neural retina was cautiously
removed from the RPE with a thin glass rod
and isolated by cutting it at the optic nerve.
The choroid with adhering RPE layer ('RPE-
choroid') was isolated by dissecting it from the
sclera with a pair of fine scissors. Sometimes it
was not possible to clearly separate neural
retina and RPE choroid from each other.
The anterior uveal tract, consisting of iris and
ciliary body, was isolated by removing the lens
from the anterior eye cup, then gently pulling
the anterior uveal tract loose from the sclera
and blotting it on dry paper to remove
adhering vitreous. Cornea and lens were dis-
carded. The ocular samples were frozen in
liquid nitrogen immediately upon dissection
and stored at -70°C until analysis.
RNAse PROTECTION ASSAY FOR RENIN
32p labelled RNA transcripts were prepared by
transcription of a 291 nucleotide antisense RNA
from a SacI/EcoRV fragment of the human
renin cDNA, subcloned into a pGEM4 vector,
using T7 RNA polymerase. The transcript com-
prised 225 nucleotides of human renin anti-
sense RNA and 66 nucleotides of vector
encoded sequence. Total RNA was isolated
from pooled human ocular tissues by lithium
chloride precipitation.20 RNAse protection
assays were performed according to Goedert
et al.21 Samples of dried RNA were dissolved in
30 [lI 80% formamide, containing 40 mM
PIPES (pH 6-8), 400 mM NaCl, 1 mM EDTA,
and 200 000 counts per minute (cpm) of the
gel-purified transcript. After denaturation at
95°C for 60 seconds and incubation at 50°C for
20 hours, RNAse digestion was performed in
300 ,ul buffer containing 40 ,ug/ml RNAse A
(Sigma, St Louis, MO, USA) and 2 ,ug/ml
RNAse Ti (Calbiochem, USA) at 37°C for
45 minutes. After digestion with proteinase K,
samples were electrophoresed on denaturing
5% polyacrylamide gels.
POLYMERASE CHAIN REACTION (PCR)
Total RNA was isolated from individual
human ocular tissue samples by a modification
of the lithium chloride method.20 After isola-
tion, total RNA samples were checked by gel
electrophoresis in a 1% agarose gel stained
with ethidium bromide. Before polymerase
chain reaction, total RNA was reversely tran-
scribed to cDNA according to Kawasaki et al.22
One ,ug of total RNA was dissolved in 20 ,lI of
a reaction mixture containing 1 mM of dATP,
dCTP, dTTP, and dGTP, 1 [lI of RNAsin
(Boehringer Mannheim GmbH, Mannheim,
Germany), 50 mM KC1, 20 mM Tris-HCl
(pH 8 4), 2-5 mM MgCl2, 10 1g/pLI nuclease-
free bovine serum albumin, and 200 U of
murine leukaemia virus reverse transcriptase
(Gibco BRL, Eggenstein, Germany). After
incubation for 45 minutes at 42°C, the tem-
perature was raised to 95°C and then quickly
lowered on ice.
For amplification of the resulting cDNA, the
volume was increased to 100 [LI with a solution
containing 50 mM KC1, 20 mM Tris-HCl
(pH 8 4), and 2-5 mM MgCl2 and 25 pmol of
upstream and downstream primers as well as
3 U of Taq polymerase (Perkin-Elmer/Cetus,
Norwalk, CT, USA). The thermal profile used
on a Perkin-Elmer/Cetus thermal cycler con-
sisted of denaturation at 950C for 1 minute,
annealing at 60°C for renin and at 55°C for
angiotensinogen and ACE, respectively, for 1
minute, and of an extension temperature of
72°C for 1 minute for 26 cycles. Human renin-
cDNA was amplified by oligonucleotides with
the following sequence AAATGAAGG-
GGGTGTCTGTGG as sense primer (bases
851-872) and AAGCCAATGCGGTTGT-
TACGC (bases 1206-1227) as antisense
primer.23 The amplification product was 376
base pairs (bp) in length spanning the second
and third exon of renin-cDNA. The sense
primer for the detection of ACE-cDNA
spanned oligonucleotide bases 492-512
(GCCTCCCCAACAAGACTGCCA), and
the antisense primer spanned base 860-880
(CCACATGTCTCCAGCCAGATG) of the
human ACE-cDNA. Human angiotensino-
gen primers were situated over the fourth and
fifth exon with the sense primer (bases
1209-1231) CTGCAAGGATCTTATGAC-
CTGC and the antisense primer (bases
1404-1426) TACACAGCAAACAGGAAT-
GGGC.°0 Specificity of amplified sequences of
the PCR products was tested by restriction
enzyme or direct sequence analysis as
described by Paul et al.10 Southern blotting
was performed as described before.24 The
amplified cDNA sequences were transferred
from 1-3% agarose gels to nylon membrane
(Pall, Dreieich, Germany) in a LKB vacuum
blot chamber using 0-25 N HCI for precipita-
tion for 30 minutes and subsequent neutralisa-
tion on 0-5 N NaOH and 1-5 M NaCl.
160
Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye
Blotting was terminated after 2 hours on
20XSSC (IXSSC: 0S15 M NaCl, 0-015 M
sodium citrate). cDNA was crosslinked to the
nylon membrane in an ultraviolet linker (No
1800, Stratagene Inc, La Jolla, CA, USA).
Membranes were prehybridised with 50%
deionised formamide, 5 XDenhardt's solution,
25 pug/ml herring sperm DNA for 4 hours.
Hybridisation was done on the same buffer
overnight at 60°C adding the corresponding
probes, which were randomly labelled using
32P-dCTP.
Labelled probes were purified on a Nensorb
column (DuPont, Wilmington, DE, USA).
Renin-cDNA was hybridised to a 1-3 kb long
BamHI/HindIII rat renin-cDNA fragment
obtained from the complete rat renin-cDNA
cloned into a pGEM4 vector. A plasmid vector
(Bluescript KS, pB35-19) containing 3334 bp
ofhuman ACE-cDNA was cut with EcoRI and
BglII to yield 1-7 and 1-6 kb of human ACE-
cDNA, which were isolated from the 3-0 kb as
probes. A 844 bp StuI fragment of human
angiotensinogen-cDNA allowed detection of
angiotensinogen-cDNA. Nylon membranes
were washed after hybridisation at room tem-
perature in 0 2XSSC and 0-1% sodium dode-
cyl sulphate for 30 minutes and three times at
56°C for 30 minutes. Blots were exposed for
18 hours at - 80°C to XAR x ray films
(Eastman Kodak Co, Rochester, NY, USA).
Results
The RNAse
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Figure 2 Demonstration of renin mRNA expression in
human eyes by the polymerase chain reaction. Southern
blot of amplification products. (1) Negative control
(without RNA); (2) human kidney; (3) retinal pigment
epithelium choroid (four individual samples); (4) neural
retina (three individual samples); (5) sclera (three
individual samples).
pooled tissue samples, because it was not sen-
sitive enough to detect renin-mRNA in indi-
vidual eye samples. Examination of individual
eye samples was possible only by using PCR.
Human kidney samples served as positive con-
trols, since in these samples renin mRNA,
angiotensinogen mRNA, and ACE mRNA are
readily detectable.1I
Using the RNAse protection assay, renin
mRNA expression could be demonstrated in
pooled RPE choroid samples, which also con-
tained some neural retinal tissue, but not in
neural retina alone or in sclera (Fig 1).
Compared with the kidney, the ocular renin
mRNA levels were low (Fig 1).
protection assay was used in
do
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Figure 1 Ocular expression of renin mRNA. Renin
mRNA was determined in different layers of the human eye
by RNAse protection assay using a human specific renin
probe. For detection, ocular tissuesfrom several patients
were pooled. (1) pUC/Sau3a (length marker); (2) human
renin probe; (3) tRNA; (4) rat kidney as specificity
control; (5) human kidney (20 pg); (6) sclera (35 ,ug);
(7) neural retina (25 ,ug); (8) retinal pigment epithelium
choroid/retina (85 ,ug).
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Figure 3 Demonstration of angiotensinogen mRNA in
human eyes by the polymerase chain reaction. (Top)
Agarose gel of amplification products. (1) PhiXI74RF Hae
III length marker; (2) negative control; (3) human kidney;
(4) neural retina; (5) retinal pigment epithelium (RPE)
choroid; (6) neural retina; (7) RPE choroid; (8) RPE
choroid. (Bottom) Southern blot of the amplification
products. (1) Empty; (2) negative control; (3) human
kidney; (4) neural retina; (5) RPE choroid; (6) neural
retina; (7) RPE choroidj, (8) RPE choroid.
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Figure 4 Demonstration of angiotensin converting enzyme
mRNA in human eyes by the polymerase chain reaction.
Southern blot of amplification products. (1) Human
kidney; (2) negative control; (3) neural retina; (4) retinal
pigment epithelium (RPE) choroid; (5) RPE choroid;
(6) neural retina.
The length of the PCR products of the dif-
ferent genes detected in the eye were identical
to the corresponding amplification signal from
the kidney (Figs 2-4). After reverse transcrip-
tion of 1 ,ug of total RNA and subsequent
amplification, all three components of the RAS
could be detected in both neural retina and
RPE choroid.
Repeatedly, renin mRNA expression
appeared to be higher in RPE choroid than in
retina alone (Fig 2), confirming our findings
with the RNAse protection assay, where renin
mRNA was detected in RPE choroid but not
neural retina. RPE choroid renin mRNA
expression was similar in samples from eyes
enucleated for choroidal melanoma and eyes
enucleated for other reasons (data not shown).
In scleral tissue, either no signal or a signal
close to the detection limit for renin gene
expression was observed, as was the case in the
RNAse protection assay. No positive signal of
renin mRNA expression was observed in the
two anterior uveal tract samples we studied
(data not shown).
Angiotensinogen and ACE gene expression
were subjected to PCR analysis only, because
of the small amount of human material avail-
able. Angiotensinogen and ACE expression
were detected both in RPE choroid and neural
retina (Figs 3 and 4). No marked differences
were found between these two ocular tissues in
the expression of either angiotensinogen or
ACE. At the end ofPCR amplification, expres-
sion of these two RAS components was absent
or only marginal in sclera (data not shown).
Discussion
This study demonstrates gene expression of
renin, angiotensinogen, and ACE in various
parts of the human eye. These peptides may
therefore be synthesised locally within the eye.
These data, together with previous findings
demonstrating the presence of RAS com-
ponents in human and cattle ocular fluids and
tissues,1-7 strongly support the existence of an
intraocular RAS independent of the circulating
RAS. Renin gene expression was found to be
highest in the RPE choroidal layer, both by
RNAse protection assay and by polymerase
chain reaction. Using the polymerase chain
reaction, renin mRNA could also be detected
in the neural retina. The polymerase chain
reaction only gives a rough measure of gene
expression. However, in view of the results
obtained with the RNAse protection assay,
expression of the renin gene is most likely
lower in the neural retina than in the RPE
choroid. In support of this assumption, the
ocular renin and angiotensin levels were found
to be lower in the retina than in the RPE
choroid.27
In human eyes, prorenin, the inactive pre-
cursor of renin, has been detected in aqueous,
vitreous, and subretinal fluid, the highest levels
being present in the latter.' Based upon these
findings and the present study, one may specu-
late about the source of prorenin in human
ocular fluids. As we have shown previously,
prorenin leakage from plasma is only a minor
source of ocular fluid prorenin.' Prorenin pro-
duced in the retina can directly enter the vitre-
ous fluid, whereas prorenin synthesised in the
choroid would first have to pass the RPE. This
layer is part of the so called 'blood-retinal bar-
rier', which is normally impermeable to
proteins such as prorenin. Under patho-
physiological conditions - for instance, in eyes
affected by proliferative retinopathy in diabetic
subjects,25 partial breakdown of the blood-
retinal barrier may occur, so that this barrier
becomes permeable to prorenin.
Two lines of evidence support prorenin pro-
duction in the posterior part (retina and/or
RPE choroid) of the eye. Firstly, as mentioned
above, prorenin levels were higher in vitreous
than in aqueous.1 Secondly, a prorenin
gradient exists in vitreous fluid with the lowest
levels present in the most anterior parts of the
vitreous.2 Others have suggested that ocular
prorenin is produced in the anterior uveal
tract,3 since they detected prorenin by
immunohistochemistry in the pars plicata of
the ciliary body. We also detected renin and
prorenin in the anterior uveal tract (ciliary
body and iris) of the bovine eye.2 However, in
the present study we failed to show renin
mRNA expression in this part of the eye. RPE
choroid and retina, therefore, are the most
likely production sites of (pro)renin in the eye.
It has not been clarified yet, whether
(pro)renin at these sites is expressed in the
vasculature (smooth muscle or endothelial
cells) or in neuronal and/or glial cells. In the
brain, renin has been demonstrated in the lat-
ter two types of cells.26 Interestingly, a recent
preliminary study localised renin in human and
rat eyes to Muller cells of the retina, in close
apposition to retinal blood vessels.27
Angiotensinogen and ACE mRNA expres-
sion could be demonstrated by polymerase
chain reaction both in neural retina and in
RPE choroid. No marked difference was found
for the expression of either angiotensinogen or
ACE between the two layers, in contrast with
our observations on renin. Scleral expression
was low or undetectable for all three compo-
nents of the RAS.
Angiotensinogen is known to be present in
brain glial and neuronal cells,28 but, as for
renin, its gene expression in the highly vascu-
larised RPE choroidal layer may also suggest a
vascular origin of the peptide. Angio-
tensinogen mRNA has been demonstrated in
vascular smooth muscle cells.29 Similarly, ACE
is widely expressed in the brain; it is found in
neuronal cells30 as well as in brain vascular
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endothelial cells.31 Ocular ACE expression
may therefore occur in either vascular or
neuroglial cells in retina and/or RPE choroid.
The co-expression of all components of the
RAS in the retina and the RPE choroid is a
prerequisite for intraocular angiotensin II pro-
duction. Angiotensin II generated locally in
retina and RPE choroid may be an important
regulator of vascular blood flow. Indeed,
angiotensin II has been reported to constrict
retinal blood vessels.'4 We have previously
demonstrated that, relative to albumin,
prorenin was twice as high in vitreous fluid
obtained from eyes affected by proliferative
diabetic retinopathy as in vitreous fluid
obtained from eyes of non-diabetic subjects.'
An activated intraocular RAS may lead to
enhanced intraocular levels of angiotensin II,
which, in view of its effects on growth,'8 19 may
contribute to the development of proliferative
retinopathy.
1 Danser AHJ, van den Dorpel MA, Deinum J, Derkx FHM,
Franken AAM, Peperkamp E, et al. Renin, prorenin, and
immunoreactive renin in vitreous fluid from eyes with and
without diabetic retinopathy. J Clin Endocrinol Metab
1989; 68: 160-6.
2 Deinum J, Derkx FHM, Danser AHJ, Schalekamp MADH.
Identification and quantification of renin and prorenin in
the bovine eye. Endocrinology 1990; 126: 1673-82.
3 Sramek SJ, Wallow IHL, Day RP, Ehrlich EN. Ocular
renin-angiotensin: immunohistochemical evidence for the
presence of prorenin in eye tissue. Invest Ophthalmol Vis
Sci 1988; 29: 1749-52.
4 Sramek SJ, Wallow IHL, Tewksbury DA, Brandt CR,
Poulsen GL. An ocular renin-angiotensin system.
Immunohistochemistry of angiotensinogen. Invest
Ophthalmol Vis Sci 1992; 33: 1627-32.
5 Ferrari-Dileo G, Ryan JW, Rockwood EJ, Davis EB,
Anderson DR. Angiotensin-converting enzyme in bovine,
feline and human ocular tissues. Invest Ophthalmol Vis Sci
1988; 29: 876-81.
6 Weinreb RN, Sandman R, Ryder MI, Friberg TR.
Angiotensin converting enzyme activity in human
aqueous humor. Arch Ophthalmol 1985; 103: 34-6.
7 Danser AHJ, Derkx FHM, Admiraal PJJ, Deinum J, de Jong
PTVM, Schalekamp MADH. Angiotensin levels in the
eye. Invest Ophthalmol Vis Sci 1994; 35: 1008-18.
8 Kumar A, Rassoli A, Raizada MK. Angiotensinogen gene
expression in neuronal and glial cells in primary cultures
of rat brain.JNeurosci 1988; 19: 287-90.
9 Dzau VJ, IngelfingerJR, Pratt RE. Regulation oftissue renin
and angiotensin gene expressions. J Cardiovasc Pharmacol
1986; 8 (suppl 10): S 1-6.
10 Paul M, Wagner J, Dzau VJ. Gene expression of the renin
angiotensin systems in human tissues: quantitative
analysis by the polymerase chain reaction. J7 Clin Invest
1993; 91: 2058-64.
11 Campbell DJ. Circulating and tissue angiotensin systems.
J Clin Invest 1987; 79: 1-6.
12 Paul M, Bachmann J, Ganten D. The tissue renin-
angiotensin systems in cardiovascular disease. Trends
Cardiovasc Med 1992; 2: 94-9.
13 Ferrari-Dileo G, Davis EB, Anderson DR. Angiotensin
binding sites in bovine and human retinal blood vessels.
Invest Ophthalmol Vis Sci 1987; 28: 1747-51.
14 Rockwood EJ, Fantes F, Davis EB, Anderson DR. The
response of retinal vasculature to angiotensin. Invest
Ophthalmol Vis Sci 1987; 28: 676-82.
15 Constad WH, Fiore P, Samson C, Cinotti AA. Use of an
angiotensin converting enzyme inhibitor in ocular hyper-
tension and primary open-angle glaucoma. Am J
Ophthalmol 1982; 105: 674-7.
16 Franken AAM, Derkx FHM, Man in 't Veld AJ, Hop WCJ,
van Rens GH, Peperkamp E, et al. High plasma prorenin
in diabetes mellitus and its correlation with some compli-
cations. J Clin Endocninol Metab 1990; 71: 1008-15.
17 Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC,
Bryer-Ash M. Increased plasma inactive renin in diabetes
mellitus: a marker of microvascular complications. N Engl
JtMed 1985; 312: 1412-7.
18 Ariza A, Fernandes LA, Inagami T, Kim JH, Manuelidis
EE. Renin in glioblastoma multiforme and its role in neo-
vascularization. AmJClin Pathol 1988; 90: 437-41.
19 Fernandez LA, Twickler J, Mead A. Neovascularization
produced by angiotensin II. 7 Lab Clin Med 1985; 105:
141-5.
20 Auffray C, Rougeon F. Purification of mouse immuno-
globulin heavy chain mRNAs from total myeloma tumor
RNA. EurJBiochem 1980; 107: 303-14.
21 Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther
RA. Cloning and sequencing of the cDNA encoding an
isoform of microtubule-associated protein tau containing
four tandem repeats: differential expression of tau protein
mRNAs in human brain. EMBOJ 1989; 8: 393-9.
22 Kawasaki ES, Clark SS, Coyne MY, Smith SD,
Champlin R, Witte ON, et al. Diagnosis of chronic
myeloid and acute lymphocytic leukemias by detection of
leukemia-specific mRNA sequences amplified in vitro.
Proc Nad Acad Sci USA 1987; 85: 5698-702.
23 Wagner J, Paul M, Ganten D, Ritz E. Gene expression and
quantification of components of the renin-angiotensin
system from human renal biopsies by the polymerase
chain reaction. J Am Soc Nephrol 1991; 2: 421 (abstract).
24 Hirsch AT, Talsness H, Schunkert H, Paul M, Dzau VJ.
Tissue-specific activation of cardiac angiotensin convert-
ing enzyme in experimental heart failure. Circ Res 1991;
69: 475-82.
25 Cunha-Vaz J, Faria de Abreu JR, Campos AJ, Figo GM.
Early breakdown of the blood-retinal barrier in diabetes.
BrJ7 Ophthalmol 1975; 59: 649-56.
26 Hermann K, Raizada MK, Sumners C, Philips MI.
Presence of renin in primary neuronal and glial cells from
rat brain. Brain Res 1987; 437: 205-13.
27 Berka JL, Stubbs AJ, Wang Z-M, Alcom D, Campbell DJ,
Skinner SL. Localisation of renin to Muller cells of the
retina. J Hypertens 1994; 12 (suppl 3): S130 (abstract).
28 Kumar A, Rassoli A, Raizda MK. Angiotensinogen gene
expression in neuronal and glial cells in primary cultures
of rat brain. J Neurosci 1988; 19: 287-90.
29 Naftilan AJ, Zuo WM, Ingelfinger JR, Ryan TJ, Pratt RE,
Dzau VJ. Localization and differential regulation of
angiotensinogen mRNA expression in the vessel wall.
J Clin Invest 1991; 87: 1300-11.
30 Paul M, Printz M, Harms E, Unger T, Lang RE, Ganten D.
Localization of renin (EC 3.4.23) and converting enzyme
(EC 3.4.15.1) in nerve endings of rat brain. Brain Res
1985; 334: 315-24.
31 Chai SY, Mendelsohn FAO, Paxinos G. Angiotensin con-
verting enzyme in rat brain visualized by quantitative in
vitro autoradiography. Neuroscience 1987; 20: 615-27.
163
